JP2022506839A5 - - Google Patents

Info

Publication number
JP2022506839A5
JP2022506839A5 JP2021524449A JP2021524449A JP2022506839A5 JP 2022506839 A5 JP2022506839 A5 JP 2022506839A5 JP 2021524449 A JP2021524449 A JP 2021524449A JP 2021524449 A JP2021524449 A JP 2021524449A JP 2022506839 A5 JP2022506839 A5 JP 2022506839A5
Authority
JP
Japan
Application number
JP2021524449A
Other languages
Japanese (ja)
Other versions
JP2022506839A (ja
JPWO2020097291A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/060208 external-priority patent/WO2020097291A1/en
Publication of JP2022506839A publication Critical patent/JP2022506839A/ja
Publication of JP2022506839A5 publication Critical patent/JP2022506839A5/ja
Publication of JPWO2020097291A5 publication Critical patent/JPWO2020097291A5/ja
Priority to JP2025016804A priority Critical patent/JP2025071108A/ja
Pending legal-status Critical Current

Links

JP2021524449A 2018-11-07 2019-11-07 Rnaがんワクチン Pending JP2022506839A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025016804A JP2025071108A (ja) 2018-11-07 2025-02-04 Rnaがんワクチン

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862757057P 2018-11-07 2018-11-07
US62/757,057 2018-11-07
US201962813900P 2019-03-05 2019-03-05
US62/813,900 2019-03-05
US201962855335P 2019-05-31 2019-05-31
US62/855,335 2019-05-31
PCT/US2019/060208 WO2020097291A1 (en) 2018-11-07 2019-11-07 Rna cancer vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025016804A Division JP2025071108A (ja) 2018-11-07 2025-02-04 Rnaがんワクチン

Publications (3)

Publication Number Publication Date
JP2022506839A JP2022506839A (ja) 2022-01-17
JP2022506839A5 true JP2022506839A5 (https=) 2022-11-15
JPWO2020097291A5 JPWO2020097291A5 (https=) 2022-11-15

Family

ID=70612163

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021524449A Pending JP2022506839A (ja) 2018-11-07 2019-11-07 Rnaがんワクチン
JP2025016804A Pending JP2025071108A (ja) 2018-11-07 2025-02-04 Rnaがんワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025016804A Pending JP2025071108A (ja) 2018-11-07 2025-02-04 Rnaがんワクチン

Country Status (6)

Country Link
US (1) US20220125899A1 (https=)
EP (1) EP3876947A4 (https=)
JP (2) JP2022506839A (https=)
CA (1) CA3118947A1 (https=)
MA (1) MA54192A (https=)
WO (1) WO2020097291A1 (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
EP3324979B1 (en) 2015-07-21 2022-10-12 ModernaTX, Inc. Infectious disease vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
CA3002912A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (vzv)
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
TW201729835A (zh) 2015-10-22 2017-09-01 現代公司 呼吸道病毒疫苗
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
HRP20220652T1 (hr) 2015-12-10 2022-06-24 Modernatx, Inc. Pripravci i postupci unosa terapijskih sredstava
MA45052A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
CN116837052A (zh) 2016-09-14 2023-10-03 摩登纳特斯有限公司 高纯度rna组合物及其制备方法
MA46584A (fr) 2016-10-21 2019-08-28 Modernatx Inc Vaccin contre le cytomégalovirus humain
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
WO2018111967A1 (en) 2016-12-13 2018-06-21 Modernatx, Inc. Rna affinity purification
US11229668B2 (en) * 2017-02-07 2022-01-25 Nantcell, Inc. Maximizing T-cell memory and compositions and methods therefor
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS Vaccine
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
MA47790A (fr) 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
WO2018187590A1 (en) 2017-04-05 2018-10-11 Modernatx, Inc. Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
WO2019036683A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. ANALYTICAL METHODS BY HPLC
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
ES2983060T3 (es) 2017-08-18 2024-10-21 Modernatx Inc Variantes de ARN polimerasa
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
AU2019345067A1 (en) 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof
MA53650A (fr) 2018-09-19 2021-07-28 Modernatx Inc Lipides peg et leurs utilisations
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
CN113795579A (zh) 2019-02-20 2021-12-14 摩登纳特斯有限公司 用于共转录加帽的rna聚合酶变体
CA3132975A1 (en) 2019-03-11 2020-09-17 Modernatx, Inc. Fed-batch in vitro transcription process
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
KR20220115569A (ko) 2019-11-18 2022-08-17 얀센 바이오테크 인코포레이티드 돌연변이 calr 및 jak2에 기반한 백신 및 이의 용도
EP3901261A1 (en) 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Coronavirus vaccine
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
IL302065A (en) * 2020-10-14 2023-06-01 Rnaimmune Inc PAN-RAS mRNA CANCER VACCINES
EP4256311A4 (en) * 2020-12-07 2025-07-09 Iogenetics Llc ADMINISTRATION OF ANTITUMOR VACCINES
US12329811B2 (en) 2021-01-11 2025-06-17 Modernatx, Inc. Seasonal RNA influenza virus vaccines
EP4301404A1 (en) * 2021-03-04 2024-01-10 Helix Nanotechnologies, Inc. Compositions including sbi adjuvants and methods of use thereof
WO2022197599A1 (en) * 2021-03-18 2022-09-22 Ne1 Inc. Cancer vaccine and method of use thereof
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
EP4147713A1 (en) * 2021-09-13 2023-03-15 OncoDNA A rna vaccine comprising an rna pool generated from a double-stranded dna pool
JP2024533501A (ja) 2021-09-13 2024-09-12 オンコディーエヌエー 患者の腫瘍の個別化された新生抗原を生成する方法
EP4147712A1 (en) * 2021-09-13 2023-03-15 OncoDNA Method to generate a double-stranded dna pool encoding neoantigens of a tumor of a patient
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2024038857A1 (ja) 2022-08-16 2024-02-22 具紀 藤堂 単純ヘルペスウイルスベクターを含む医薬組成物
EP4364752A1 (en) 2022-11-07 2024-05-08 OncoDNA Improved vaccine
EP4648793A1 (en) * 2023-01-11 2025-11-19 ModernaTX, Inc. Personalized cancer vaccines
WO2024238587A1 (en) 2023-05-17 2024-11-21 Tesaro, Inc. Novel use of an inhibior of the a poly-adp ribose polymerase (parp) in the treatment of cancer
WO2025087266A1 (en) 2023-10-23 2025-05-01 Abogen Biosciences (Shanghai) Co., Ltd. Immunomodulatory mrna cassettes, and uses thereof
WO2025117816A1 (en) * 2023-12-01 2025-06-05 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
CN121064279A (zh) * 2024-06-04 2025-12-05 复旦大学附属中山医院 一种抗肝癌hla-a*11型疫苗及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012116715A1 (en) * 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
HRP20211595T1 (hr) * 2011-05-24 2022-01-21 BioNTech SE Individualizirana cjepiva protiv raka
WO2014082729A1 (en) * 2012-11-28 2014-06-05 Biontech Ag Individualized vaccines for cancer
EP2958588B1 (en) * 2013-02-22 2017-08-23 CureVac AG Combination of vaccination and inhibition of the pd-1 pathway
CN118750591A (zh) * 2013-04-07 2024-10-11 博德研究所 用于个性化瘤形成疫苗的组合物和方法
KR20180004820A (ko) * 2015-05-15 2018-01-12 큐어백 아게 적어도 하나의 mRNA 구성의 투여를 포함하는 신규 프라임-부스트 요법
WO2017020026A1 (en) * 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
EP3364949A4 (en) * 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
WO2018115525A1 (en) * 2016-12-23 2018-06-28 Curevac Ag Lassa virus vaccine
ES2973040T3 (es) * 2017-01-27 2024-06-18 Methodist Hospital Plataforma de estructura de núcleo/cáscara para inmunoterapia
EP3576751A4 (en) * 2017-02-01 2021-08-04 ModernaTX, Inc. RNA ANTI-CANCER VACCINES
CA3050614A1 (en) * 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy

Similar Documents

Publication Publication Date Title
JP2022506839A5 (https=)
BR112019017762A2 (https=)
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016138A2 (https=)
BR112019016142A2 (https=)
BR112021017732A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)
BR112021012348A2 (https=)
BR112021018250A2 (https=)
BR112021018584A2 (https=)